At the end of September 2025, a gene therapy company released results from a clinical trial showing that a breakthrough procedure reduced the progression of Huntington’s symptoms by 75 percent over three years. Researchers collected data from 12 participants who received the therapy and compared the data with two types of control groups. The company’s drug,
Huntington’s disease gene therapy: FDA reversal delays AMT-130 originally appeared in KevinMD.com.
Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.